Literature DB >> 25092848

Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals.

Cassie Frank1, David U Himmelstein2, Steffie Woolhandler3, David H Bor4, Sidney M Wolfe5, Orlaith Heymann6, Leah Zallman7, Karen E Lasser8.   

Abstract

After approval, many prescription medications that patients rely on subsequently receive new black-box warnings or are withdrawn from the market because of safety concerns. We examined whether the frequency of these safety problems has increased since 1992, when the Prescription Drug User Fee Act, legislation designed to accelerate the drug approval process at the Food and Drug Administration, was passed. We found that drugs approved after the act's passage were more likely to receive a new black-box warning or be withdrawn than drugs approved before its passage (26.7 per 100.0 drugs versus 21.2 per 100.0 drugs at up to sixteen years of follow-up). We could not establish causality, however. Our findings suggest the need for reforms to reduce patients' exposure to unsafe drugs, such as a statement or symbol in the labeling, medication guides for patients, and marketing materials indicating that a drug was approved only recently. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Pharmaceuticals; Quality Of Care

Mesh:

Substances:

Year:  2014        PMID: 25092848     DOI: 10.1377/hlthaff.2014.0122

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  43 in total

Review 1.  Human-relevant preclinical in vitro models for studying hepatobiliary development and liver diseases using induced pluripotent stem cells.

Authors:  Pooja Chaudhari; Lipeng Tian; Zhaohui Ye; Yoon-Young Jang
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-26

2.  Enhancing postmarketing surveillance: continuing challenges.

Authors:  Dustin D French; Curtis E Margo; Robert R Campbell
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

3.  Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.

Authors:  Jean-David Zeitoun; Jérémie H Lefèvre; Nicholas S Downing; Henri Bergeron; Joseph S Ross
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

Review 4.  Evaluation of technologies approved for supplemental payments in the United States.

Authors:  Timothy J Judson; Sanket S Dhruva; Rita F Redberg
Journal:  BMJ       Date:  2019-06-17

5.  Cost recovery by Health Canada and drug safety: a time-series analysis.

Authors:  Joel Lexchin
Journal:  CMAJ Open       Date:  2018-10-18

6.  Effects of the US Food and Drug Administration Boxed Warning of Erythropoietin-Stimulating Agents on Utilization and Adverse Outcome.

Authors:  John Bian; Brian Chen; Dawn L Hershman; Norman Marks; LeAnn Norris; Richard Schulz; Charles L Bennett
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

7.  ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors.

Authors:  Annie Yang; Shrujal Baxi; Deborah Korenstein
Journal:  J Oncol Pract       Date:  2018-01-03       Impact factor: 3.840

8.  New and incremental FDA black box warnings from 2008 to 2015.

Authors:  Michael T Solotke; Sanket S Dhruva; Nicholas S Downing; Nilay D Shah; Joseph S Ross
Journal:  Expert Opin Drug Saf       Date:  2017-12-17       Impact factor: 4.250

Review 9.  Overview of the First Natural Language Processing Challenge for Extracting Medication, Indication, and Adverse Drug Events from Electronic Health Record Notes (MADE 1.0).

Authors:  Abhyuday Jagannatha; Feifan Liu; Weisong Liu; Hong Yu
Journal:  Drug Saf       Date:  2019-01       Impact factor: 5.606

10.  Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation.

Authors:  Daniel B Horton; Tobias Gerhard; Amy Davidow; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-08-31       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.